​

Faeth Therapeutics (FTH) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

FTH Stock Forecast

Faeth Therapeutics (FTH) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $56.60, with a high of $60.00 and a low of $50.00. This represents a 98.25% increase from the last price of $28.55.

FTH Stock Rating

Faeth Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

FTH Price Target Upside V Benchmarks

TypeNameUpside
StockFaeth Therapeutics98.25%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts255
Avg Price Target$58.00$56.60$56.60
Last Closing Price$28.55$28.55$28.55
Upside/Downside103.15%98.25%98.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 2628---10
Jul, 26-7---7
Jun, 26-7---7
May, 26-41--5
Apr, 26-11--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 31, 2026Sean McCutcheonRaymond James$56.00$28.8294.31%96.15%
Jul 27, 2026Oppenheimer$60.00$29.24105.20%110.16%
Jun 25, 2026Jack AllenRobert W. Baird$57.00$24.67131.05%99.65%
Jun 22, 2026H.C. Wainwright$60.00$17.82236.70%110.16%
May 28, 2026Christopher LiuLoop Capital Markets$50.00$16.65200.30%75.13%
May 13, 2024Sudan LoganathanStephens$5.00$1.57218.47%-82.49%
Dec 13, 2022Citigroup$6.00$1.74244.83%-78.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 31, 2026Raymond JamesOutperforminitialise
Jul 27, 2026OppenheimerOutperformOutperforminitialise
Jul 20, 2026CitigroupBuyOutperforminitialise
Jun 22, 2026H.C. WainwrightNeutralBuyinitialise
Jun 11, 2026BTIGBuyinitialise
Jun 04, 2026Cantor FitzgeraldOverweightOverweighthold
May 29, 2026Cantor FitzgeraldOverweightinitialise
May 22, 2026CitigroupBuyBuyinitialise
Oct 30, 2025H.C. WainwrightBuyNeutraldowngrade
Aug 05, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported$-16.72-----
Avg Forecast$-18.17$-132.38$-6.53$-5.75$-5.26$-4.96
High Forecast$-18.17$-132.38$-6.53$-2.70$-5.26$-4.96
Low Forecast$-18.17$-132.38$-6.53$-8.80$-5.26$-4.96
Surprise %-7.98%-----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported------
Avg Forecast---$16.83M$74.20M$137.15M
High Forecast---$16.83M$74.20M$137.15M
Low Forecast---$16.83M$74.20M$137.15M
Surprise %------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29 Dec 30
Dec 25Dec 26Dec 27Dec 28Dec 29Dec 30
Reported$-21.09M-----
Avg Forecast$-22.91M$-166.91M$-8.23M$-7.25M$-6.63M$-6.26M
High Forecast$-22.91M$-166.91M$-8.23M$-3.40M$-6.63M$-6.26M
Low Forecast$-22.91M$-166.91M$-8.23M$-11.09M$-6.63M$-6.26M
Surprise %-7.96%-----

FTH Forecast FAQ

Is Faeth Therapeutics stock a buy?

Faeth Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Faeth Therapeutics is a favorable investment for most analysts.

What is Faeth Therapeutics's price target?

Faeth Therapeutics's price target, set by 4 Wall Street analysts, averages $56.6 over the next 12 months. The price target range spans from $50 at the low end to $60 at the high end, suggesting a potential 98.25% change from the previous closing price of $28.55.

How does Faeth Therapeutics stock forecast compare to its benchmarks?

Faeth Therapeutics's stock forecast shows a 98.25% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Faeth Therapeutics over the past three months?

  • August 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Faeth Therapeutics’s EPS forecast?

Faeth Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-132, marking a 691.75% increase from the reported $-16.72 in 2025. Estimates for the following years are $-6.53 in 2027, $-5.75 in 2028, $-5.26 in 2029, and $-4.96 in 2030.

What is Faeth Therapeutics’s revenue forecast?

Faeth Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, followed by $16.83M for 2028, $74.2M for 2029, and $137.15M for 2030.

What is Faeth Therapeutics’s net income forecast?

Faeth Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-167M, representing an 691.58% increase from the reported $-21.085M in 2025. Projections indicate $-8.231M in 2027, $-7.246M in 2028, $-6.632M in 2029, and $-6.257M in 2030.